LAWRENCE, KS – CritiTech, Inc. has named Mechanical Systems, Inc. (MSI) of Wichita, Kan., as its official and exclusive supplier of fine-particle drug manufacturing equipment.
As a long-time partner, MSI has been instrumental in helping CritiTech develop manufacturing equipment that produces commercial quantities of fine-particle drugs using CritiTech’s proprietary supercritical fluid carbon dioxide-based technologies.
MSI has decades of experience designing and constructing manufacturing equipment for the biotechnology and pharmaceutical industries, serving clients such as Boehringer-Ingelheim, Hospira, Bayer, Abbott, Pfizer, and Shering-Plough.
“This is an ideal match for both companies,” said Matthew McClorey, president of CritiTech. “CritiTech is in the business of enabling new and improved drugs with our technology, not constructing manufacturing equipment. Thus, the relationship with MSI allows us to focus on what we do best. We are extremely fortunate to have MSI as our exclusive equipment supplier. Its engineering experience and expertise is outstanding.”
MSI has already built, designed and installed equipment that CritiTech is currently using to provide fine-particle drug development services to its clients. The exclusive supplier agreement with MSI ensures CritiTech will have the commercial engineering expertise required to scale its technology and meet customers’ drug manufacturing demands.
Equipment from MSI will also be used to produce Nanotax®, a novel, fine-particle reformulation of paclitaxel to treat intraperitoneal cancers enabled by CritiTech’s technology. A Phase I Trial for Nanotax® that produced positive results was recently completed.
“MSI is very excited about the partnership with CritiTech,” said Greg Johnson, president of MSI. “CritiTech’s technology is unique and very valuable, as evidenced by its ovarian cancer drug, Nanotax. Just as the technology was used to develop Nanotax, we believe it can be used to develop other drugs that are more effective, safer and better tolerated.”
Download slides from a recent visual introduction of MSI, highlighting our custom fabrication abilities
Lawrence, KS - CritiTech, Inc., a pharmaceutical company that improves and enables the delivery of therapeutic molecules using supercritical fluid technology to produce and deposit particles of active pharmaceutical ingredients (API), and Mechanical Systems Inc. (MSI), a premier mechanical systems solutions provider for the pharmaceutical industry, announce the formation of a strategic alliance. The alliance creates a long term exclusive arrangement for the manufacture and sales of crystallizer units (R&D through commercial production scale) based on CritiTech’s technology and proprietary designs. According to Dr. David Johnston, CEO of CritiTech, Inc, “The establishment of this formal Alliance marks a major milestone for both companies in readying us for the future deployment of our technology. It also marks a transition point for our company in the ability to produce clinically and potentially commercial scale quantities of active pharmaceutical ingredients and to offer that capability to our collaborators.”
Over the past two years, CritiTech and Mechanical Systems Inc. have created and validated a supercritical fluid crystallizer that is capable of continuously processing pure submicron size particles of active pharmaceuticals in quantities that were once thought unattainable with this type of process. CritiTech continues to expand its in-house GMP manufacturing capabilities (currently several Kg per week) at its Lawrence, Kansas facility, and to develop the next generation crystallizer which will further increase production capability and capacity. This also marks another important step for MSI as it continues to expand into the pharmaceutical industry. Greg Johnson, Principal of MSI, states, “Over the years, our involvement in the pharma industry has been as an applications support firm. This new alliance opens possibilities of greater involvement in pharmaceutical development and production. The engineering and assembly of the supercritical fluid crystallizer has highlighted our unique skills. We look forward with focus and excitement to these new horizons.” With their new alliance, CritiTech and Mechanical Systems Inc. will make this technology available to companies with drug delivery challenges and other unmet pharmaceutical needs.
Copyright Mechanical Systems, Inc. 2012. All Rights Reserved.